NCT07769151 BIO-FUNCTION for Prediction Non Relapse Mortality in Transplant and Cell Therapy
| NCT ID | NCT07769151 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Henry Ford Health System |
| Condition | Mortality Prediction |
| Study Type | OBSERVATIONAL |
| Enrollment | 124 participants |
| Start Date | 2026-09-01 |
| Primary Completion | 2030-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 124 participants in total. It began in 2026-09-01 with a primary completion date of 2030-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is test if combination of physical tests and blood tests drawn before SCTCT can predict NRM.
Eligibility Criteria
Inclusion Criteria: * patients \>18 year old planned for SCTCT Exclusion Criteria: * Pregnancy, prisoners , Patients with a serious medical or psychiatric illness likely to interfere with participation in this clinical study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07769151 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Mortality Prediction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07769151 currently recruiting?
Yes, NCT07769151 is actively recruiting participants. Contact the research team at sfarhan1@hfhs.org for enrollment information.
Where is the NCT07769151 trial being conducted?
This trial is being conducted at Detroit, United States.
Who is sponsoring the NCT07769151 clinical trial?
NCT07769151 is sponsored by Henry Ford Health System. The trial plans to enroll 124 participants.